The World's Youngest Stem Cells. Infinite Potential.
Auvum Biotech has exclusive access to hTSC derived at โ6 months before birth โ the youngest and most potent stem cells available globally. Combined with umbilical cord MSC-derived exosomes, lineage cells, peptides, and Yamanaka Factor proteins, we are advancing regenerative medicine worldwide.
hTSC Stem Cells
Pre-implantation trophoblast stem cells โ the world's youngest and most potent stem cell source, validated by NIH.
Learn MoreUC-MSC Stem Cells
Umbilical cord mesenchymal stem cells providing a clinically validated platform for exosome production and lineage programming.
Learn MoreLineage Cells
Organ-specific repair cells preprogrammed for cardiac, neural, hepatic, and musculoskeletal regeneration.
Learn MoreYamanaka Factors
Cellular reprogramming proteins that reverse age-associated decline โ advancing longevity medicine and chronic disease management.
Learn MoreAccess to the World's Youngest Stem Cells
Auvum Biotech is a cutting-edge biotechnology company with exclusive access to human Trophoblast Stem Cells (hTSC) derived at the pre-implantation stage โ approximately 6 months before birth. These represent the youngest and most biologically active stem cell source available anywhere in the world, validated by the NIH National Institute on Aging.
We also work with umbilical cord mesenchymal stem cells (UC-MSC), providing a clinically validated platform for exosome production, lineage-specific cell programming, peptide research, and Yamanaka Factor protein therapies. Our lineage cells are preprogrammed to repair specific organs โ cardiac, neural, hepatic, and musculoskeletal โ through precise directed differentiation protocols.
Our mission is to bring this research into the public domain โ educating and collaborating with clinics, research institutions, universities, and governments worldwide.
NIH Validated
hTSC exosomes validated by the National Institute on Aging at NIH
cGMP Certified
Manufacturing under current Good Manufacturing Practices
Global Reach
Partnerships across 12+ countries on multiple continents
Lineage Programming
Preprogrammed cells directed to repair specific organs and targeted cell types
Research teams collaborate across state-of-the-art facilities worldwide
hTSC vs. MSC Exosomes A Scientific Comparison
Auvum Biotech has exclusive access to human Trophoblast Stem Cells (hTSC) derived at the pre-implantation stage โ approximately 6 months before birth. Younger cells have increased bio-activity and produce exosomes that are uniquely powerful in counteracting cellular senescence, validated by the NIH National Institute on Aging.
Younger cells have increased bio-activity, producing exosomes more effective for counteracting cellular senescence
National Institute on Aging Recognition
The unique properties of hTSC exosomes attracted the interest of National Institute of Aging (NIA) researchers at the National Institutes of Health (NIH). The NIA demonstrated that these pre-placental trophoblast stem cell exosomes are highly biologically active and uniquely powerful in reversing cell-aging (cellular senescence), protecting against DNA damage, and stimulating proliferation and tissue repair.
Comparison of Exosome Cell Types
hTSC presents many advantages from different types of exosome sources
| Attribute | hTSC | MSC | iPSC | Animal | Plant |
|---|---|---|---|---|---|
Developmental Stage Age of stem cell source | |||||
Exosome Production Ability to produce exosomes | |||||
Ethical Sourcing Regulatory compliance | |||||
Lineage Programming Directed differentiation capability | |||||
Clinical Validation Published research support | |||||
Scalability Manufacturing capacity |
Source: Auvum Biotech Research, 2026. hTSC = Human Trophoblast Stem Cell. MSC = Mesenchymal Stem Cell.
Advancing Regenerative Medicine Through Science
We collaborate with leading research institutions to validate our therapies and expand the frontiers of regenerative medicine. Our protocols are designed to meet the highest standards of scientific rigor and clinical efficacy.
hTSC Stem Cell Biology
Human Trophoblast Stem CellsAuvum holds exclusive access to the world's youngest stem cells โ pre-implantation hTSC at โ6 months โ delivering unparalleled regenerative potency and bio-activity across all therapeutic applications.
Exosome Science
Extracellular Vesicle PlatformsOur dual-platform exosome technology combines hTSC and UC-MSC sources to deliver the broadest and most potent regenerative toolkit available โ validated across immune, metabolic, neurological, and dermal pathways.
Lineage Programming
Directed Cell DifferentiationProprietary lineage programming protocols enable directed differentiation of hTSC into organ-specific repair cells โ including cardiomyocytes, hepatocytes, neurons, and chondrocytes โ for targeted therapeutic delivery.
Peptide Therapeutics
Bioactive Peptide EngineeringAuvum's peptide research focuses on identifying and synthesizing bioactive sequences derived from hTSC exosome cargo โ enabling targeted signaling for tissue repair, immune modulation, and cellular rejuvenation.
Regenerative Protocols
Clinical-Grade FormulationsEvidence-based clinical protocols developed in collaboration with partner institutions define standardized dosing, administration routes, and patient selection criteria for all Auvum regenerative therapies.
Yamanaka Factor Research
Cellular Reprogramming ScienceAuvum's research into Yamanaka Factor proteins explores partial cellular reprogramming as a mechanism for reversing age-associated cellular decline โ with applications in longevity medicine and chronic disease management.
The Power of
Exosomes are nano-sized extracellular vesicles that facilitate cell-to-cell communication. Derived from the world's youngest stem cells, Auvum's exosomes carry bioactive molecules including proteins, lipids, and nucleic acids that promote tissue regeneration, reduce inflammation, and enhance cellular repair.
Molecular Cargo Comparison
Auvum hTSC Exosomes
Pre-implantation trophoblast stem cells (~6 months pre-birth)
Pre-Implantation Origin
Derived ~6 months before birth โ the youngest biologically active human cell source available globally
Superior Protein Cargo
1,300+ unique proteins vs ~340 in MSC exosomes โ a 3.8ร richer regenerative payload
NIH-Validated Senescence Reversal
Demonstrated reversal of cellular aging, DNA damage protection, and tissue repair stimulation
Exclusive Availability
Patented pre-COVID source, exclusively accessible through Auvum Biotech's proprietary platform
Standard UC-MSC Exosomes
Umbilical cord mesenchymal stem cells (post-birth)
Clinical Track Record
Extensively validated in clinical settings with established safety and efficacy profiles
Scalable Production
High-volume exosome production for large-scale research and therapeutic applications
Lineage Flexibility
Robust platform for directed differentiation into organ-specific repair cell lineages
Regulatory Pathway
Well-characterized regulatory framework supporting clinical translation globally
Data based on NIH-validated comparative proteomics and transcriptomics analysis. hTSC exosomes demonstrate superior bioactivity across all measured parameters.
Seven Domains of Therapeutic Impact
Our hTSC and UC-MSC-derived exosomes contain proteins and miRNAs that regulate pathways across seven critical therapeutic categories โ each domain also served by lineage-specific preprogrammed cells engineered for targeted organ repair.
Immune Health
Modulating immune response through complement proteins and immunoglobulins
Anti-Inflammation
Reducing chronic inflammation via serpins and apolipoproteins
Wound Healing
Accelerating tissue repair through collagen and growth factors
Lipid Transport
Optimizing cholesterol metabolism and nutrient delivery
Metabolic Health
Supporting metabolic function and energy homeostasis
Neuro Health
Neuroprotection and cognitive function enhancement
Skin Health
Dermal rejuvenation via collagen and matrix proteins
Data derived from proteomic analysis of hTSC and UC-MSC exosomes โ NIH validated research
Cutting-Edge Biotech Innovation
Our proprietary technology platform ensures consistent, high-quality production of therapeutic cells and exosomes. We employ advanced cryopreservation, bioprocessing, and quality assurance protocols to deliver the most effective regenerative therapies.
Comparative Potency
Biological Activity Index
Therapeutic Pipeline
Cell Isolation
hTSC and UC-MSC harvesting under sterile GMP conditions
Culture & Expansion
Proprietary media formulation for optimal cell proliferation
Exosome Extraction
Ultracentrifugation yielding 1,300+ proteins and 600+ miRNAs
Lineage Programming
Directed differentiation into organ-specific repair cells
Quality & Distribution
cGMP-compliant testing and cold-chain delivery to global partners
Collaborating Worldwide for Better Health
Auvum Biotech partners with clinics, research institutions, universities, and governments across multiple continents to advance regenerative medicine and bring cutting-edge therapies to patients in need.
Clinics & Hospitals
Licensed medical facilities integrating regenerative therapies into patient care protocols worldwide.
Become a PartnerResearch Institutions
Leading research centers conducting peer-reviewed studies on hTSC and UC-MSC exosome applications.
Become a PartnerUniversities
Academic institutions collaborating on curriculum development, clinical trials, and translational research.
Become a PartnerGovernment Agencies
National health ministries and regulatory bodies advancing regenerative medicine policy and approval frameworks.
Become a PartnerAustin, Texas
United States
HeadquartersBogotรก
Colombia
Regional OfficeMumbai
India
ExpandingManila
Philippines
ExpandingReady to Partner with Auvum?
Join our global network of clinics, research institutions, and universities advancing regenerative medicine.
Building the Future of Regenerative Medicine
We provide specialized training and certification programs for physicians, researchers, and clinical staff. Our curriculum covers the latest advances in stem cell therapy, exosome science, and regenerative medicine protocols.
Stem Cell Therapy Certification
Comprehensive certification program covering hTSC and UC-MSC clinical applications for licensed physicians and researchers.
Request AccessExosome Clinical Protocols
Evidence-based clinical protocols for exosome administration, dosing, and patient selection across therapeutic indications.
Request AccessRegenerative Medicine Workshops
Hands-on workshops covering laboratory techniques, cell handling, and quality assessment for clinical staff.
Request AccessLive Scientific Webinars
Monthly live sessions with Auvum researchers presenting the latest findings in regenerative medicine and stem cell science.
Request AccessUniversity Research Programs
Collaborative research programs for academic institutions seeking access to hTSC and UC-MSC platforms for peer-reviewed studies.
Request AccessClinical Integration Consulting
One-on-one consulting for clinics integrating regenerative therapies, covering regulatory compliance, patient protocols, and outcomes tracking.
Request Access"Our mission is to bring regenerative medicine research into the public domain โ making cutting-edge science accessible to every clinician, researcher, and institution committed to advancing human health."
Peer-Reviewed Research
Auvum Biotech publishes regularly in leading peer-reviewed journals, advancing the scientific understanding of regenerative medicine and validating our therapeutic approaches through rigorous clinical and preclinical studies.
Characterization of hTSC-Derived Exosomes: Proteomic and miRNA Profiling
NIH Collaborative Study
Comprehensive untargeted proteomics and RNA sequencing analysis identifying 1,300+ proteins and 600+ miRNAs across seven therapeutic categories in pre-implantation-derived exosomes.
Comparative Potency Analysis: hTSC vs. Conventional Stem Cell-Derived Exosomes
Regenerative Medicine Review
Head-to-head comparison demonstrating superior regenerative capacity of hTSC-derived exosomes versus amniotic fluid, umbilical cord, bone marrow, and iPSC-derived sources.
UC-MSC Derived Exosomes: Immunomodulatory Properties and Clinical Applications
Stem Cell Research & Therapy
Comprehensive analysis of umbilical cord mesenchymal stem cell-derived exosomes demonstrating robust immunomodulatory capacity and multi-lineage differentiation potential for clinical regenerative applications.
Lineage-Specific Cell Programming for Targeted Organ Repair
Nature Regenerative Medicine
Novel directed differentiation protocols producing cardiac, neural, hepatic, and musculoskeletal lineage cells from hTSC and UC-MSC sources, engineered for precision organ-targeted therapeutic intervention.
Yamanaka Factor Proteins as Therapeutic Agents in Cellular Rejuvenation
Cellular Reprogramming Journal
Comprehensive review of Oct4, Sox2, Klf4, and c-Myc transcription factors and their potential applications in age reversal and tissue degeneration therapy.
Anti-Senescence Properties of Pre-Implantation Derived Extracellular Vesicles
Journal of Gerontology
NIH-validated study demonstrating the capacity of hTSC exosomes to counteract cellular senescence, enhance cell proliferation, and protect against DNA damage.
Clinical Protocol Development for Exosome-Based Regenerative Therapies
Clinical Practice Guidelines
Standardized treatment protocols for the clinical application of hTSC-derived exosomes across orthopedic, dermatological, neurological, and metabolic indications.
Global Regulatory Landscape for Stem Cell-Derived Biologics
Regulatory Affairs Review
Analysis of regulatory frameworks across 12+ countries governing the clinical use of hTSC, UC-MSC-derived exosomes, lineage cells, and extracellular vesicle therapies.
Partner With Auvum Biotech
Interested in collaboration, research partnerships, or clinical applications? Contact our team to discuss how Auvum Biotech can support your regenerative medicine initiatives.
Austin, Texas
HQ N. America
Bogotรก, Colombia
HQ S. America
India
Expanding
Philippines
Expanding